Prognostic Effect of KELIM Score of Prostate-Specific Antigen in Hormone-Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways

Basit Öğe Kaydı
dc.contributor.authorIlhan, Yusuf
dc.contributor.authorAraz, Murat
dc.contributor.authorGurbuz, Ali Fuat
dc.contributor.authorUrvay, Semiha
dc.contributor.authorUrun, Muslih
dc.contributor.authorErcek, Berrak Mermit
dc.contributor.authorOzilice, Ozden
dc.date.accessioned2026-01-24T12:30:51Z
dc.date.available2026-01-24T12:30:51Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground The prognostic value of the PSA ELIMination rate constant K (PRO-KELIM) score was investigated in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel androgen receptor inhibitors. Methods This multicenter retrospective study included 160 patients diagnosed with prostate adenocarcinoma between 2011 and 2024 who received enzalutamide or abiraterone during the mCSPC and had at least three PSA measurements within the first 100 days of treatment. The patients were categorized into favorable (PRO-KELIM >= 1.0) and unfavorable (PRO-KELIM < 1.0) groups. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier survival analysis and Cox regression. Results Median PFS was significantly higher in the favorable group than in the unfavorable group (not reached vs. 40.0 months, p < 0.001). The estimated 2-year PFS rates in the favorable and unfavorable groups were 78% and 52%, respectively. In multivariate analyses, a high PRO-KELIM score (HR 2.99; 95% CI 1.35-6.66, p = 0.007) and good initial response to treatment (p = 0.001) were independent favorable prognostic factors for PFS. The median OS did not differ significantly between the groups (p = 0.27). PRO-KELIM score was not an independent prognostic factor for OS (p = 0.76). Conclusion These findings suggest that the PRO-KELIM score can be a valuable prognostic tool in the mCSPC to assess early treatment response and predict disease progression.
dc.description.sponsorshipThe authors received no specific funding for this work.
dc.description.sponsorshipThe authors have nothing to report.
dc.identifier.doi10.1002/pros.70098
dc.identifier.issn0270-4137
dc.identifier.issn1097-0045
dc.identifier.pmid41277135
dc.identifier.scopus2-s2.0-105022697154
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1002/pros.70098
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5483
dc.identifier.wosWOS:001621479900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofProstate
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260121
dc.subjectAndrogen receptor inhibitors
dc.subjectMetastatic castration-sensitive prostate cancer
dc.subjectProstate-specific antigen (PSA)
dc.subjectThe ELIMination rate constant K (KELIM)
dc.titlePrognostic Effect of KELIM Score of Prostate-Specific Antigen in Hormone-Sensitive Prostate Cancer Patients Treated With Novel Androgen Receptor Inhibitors: Pioneering New Ways
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu